Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Plus Lenvatinib vs Lenvatinib Monotherapy in Unresectable HCC
NCT07408804Recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Objective Response Rate at 3 months. Started Apr 2025; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07408804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408804.